As Oxali is known to induce ICD and T-cell priming, we investigated whether its ability to potentiate the immune rejection of IgA+ plasmocyte-depleted or anti–PD-L1–treated low MHC-I prostate tumors also entails effects on the recognition and killing step of the cancer-immunity cycle, which depends on CTL–MHC-I interactions (16, 25). Here, CD274 is linked to cancer.